Skip to main content
. 2022 Jan 11;13:245. doi: 10.1038/s41467-021-27921-1

Fig. 2. MAPK4 activates AKT in human TNBC cells.

Fig. 2

a Western blots on MAPK4 expression in various human TNBC cell lines and MCF10A, a “normal” human mammary epithelial cell line. H157 and H1299 are human non-small cell lung cancer cell lines expressing high levels of MAPK4 as we previously reported. b Western blots on engineered MDA-MB-231, HCC1937, HS578T, and SUM159 cells with 4 μg/ml Dox-induced knockdown of MAPK4 (iG2, iG4) or control (iNT). c Western blots on engineered SUM159, MDA-MB-468, HCC1395, and HCC1806 cells with 0.5 μg/ml Dox-induced expression of MAPK4 (iMAPK4) or control (iCtrl). d CRISPR/Cas9 technology was used to knockout MAPK4 in MDA-MB-231 cells (clone# 1, 2, 3) and SUM159 cells (clone# 1, 2). Western blots were used to compare AKT phosphorylation and activation among these cells. e MAPK4 was ectopically expressed in the MDA-MB-231 MAPK4-knockout cells (clone# 3) and SUM159 MAPK4-knockout cells (clone# 2). Western blots were used to detect AKT phosphorylation and activation. Data are representative of at least three independent experiments.